The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | How will the PARADIGM trial change the mCRC treatment landscape?
The phase III PARADIGM study (NCT02394795) recently demonstrated the efficacy of panitumumab plus mFOLFOX6 in patients with RAS wildtype metastatic colorectal cancer (mCRC). Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, comments on the consequences of the trial findings. Anti-EFGR therapies such as panitumumab should become the standard of care as a first line therapy for RAS wildtype mCRC. However, the current regimen of bevacizumab with mFOLFOX6 may be given to patients if there are concerns with toxicity. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
